Pancreatic Cancer Research

ResearcherFriedrich-Alexander-Universität Erlangen-NürnbergActive in the last 2 years

Jinping Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5537-5131; OpenAlex author ID A5100675063. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 3

  1. Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. Co-author DOI 10.1038/s41420-024-01890-y↗
  2. Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer. Co-author DOI 10.3390/cancers15194842↗
  3. CDX2 inhibits pancreatic adenocarcinoma cell proliferation via promoting tumor suppressor miR-615-5p. Last author DOI 10.1007/s13277-015-3900-6↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nathalie Britzen‐Laurent · 2 shared papers, 2023–2024 · strength 0.33
  2. Robert Grützmann · 2 shared papers, 2023–2024 · strength 0.33
  3. Christian P. Pilarsky · 2 shared papers, 2023–2024 · strength 0.33
  4. Yanxi Lu · 1 shared paper, 2024 · strength 0.15
  5. Hai Yang · 1 shared paper, 2024 · strength 0.15
  6. Duo Yun · 1 shared paper, 2024 · strength 0.15
  7. Bin Lan · 1 shared paper, 2024 · strength 0.15
  8. Eva Lentsch · 1 shared paper, 2024 · strength 0.15
  9. Hang He · 1 shared paper, 2024 · strength 0.15
  10. Marc P. Stemmler · 1 shared paper, 2024 · strength 0.15
  11. Shuman Zhang · 1 shared paper, 2024 · strength 0.15
  12. Hao Yang · 1 shared paper, 2024 · strength 0.15
  13. Debabrata Mukhopadhyay · 1 shared paper, 2024 · strength 0.15
  14. Andrew Victor Biankin · 1 shared paper, 2024 · strength 0.15
  15. Yuanyuan Jiang · 1 shared paper, 2016 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.